Dr. Oana-Sonia Cismas

Membru in:

• Societatea Romana de Hematologie
• Societatea Europeana de Hematologie

• 2019 - 2022: Doctor in Stiinte Medicale, Departamentul de Oncologie-Patologie, Instututul Karolinska, Stockholm, Suedia
• 2008 - 2014: Universitatea de Medicina si Farmacie "Victor Babes", Timisoara

• 2018 - 2020 - Competenta in Genetica Medicala, cursul acreditat “PROGEN- SMIS 107623“, Universitatea de Medicina si Farmacie "Victor Babes", Timisoara

• Ciprian Tomuleasa, Cristina Selicean, Sonia Cismas, Anca Jurj, Mirela Marian, Delia Dima, Sergiu Pasca, Bobe Petrushev, Vlad Moisoiu, Wilhelm-Thomas Micu, Anna Vischer, Kanza Arifeen, Sonia Selicean, Mihnea Zdrenghea, Horia Bumbea, Alina Tanase, Ravnit Grewal, Laura Pop, Carmen Aanei, Ioana Berindan-Neagoe Minimal residual disease in chronic lymphocytic leukemia: A consensus paper that presents the clinical impact of the presently available laboratory approaches Crit Rev Clin Lab Sci 2018 Mai 25, PMID: 29801428
• Crudden C, Song D, Cismas S, Trocmé E, Pasca S, Calin GA, Girnita A, Girnita L. Below the Surface: IGF-1R Therapeutic Targeting and Its Endocytic Journey Cells 2019 Oct 9, PMID: 31600876
• Crudden C,  Takashi S, Song D, Dragomir MP, Cismas S, Serly J, Nedelcu D, Fuentes-Mattei, Tica A, Calin GA, Girnita A and Girnita L G protein-coupled receptor kinase 2 inhibition promotes unbiased Insulin growth factor 1 receptor downregulation and restrains malignant cell growth Cancer Research 2020 Nov 6; PMID: 33158816
• Song D, Cismas S,  Trocme E, Worrall C, Lin T, Zheng H, Seregard S Girnita A and GIRNITA L IGF-1R is a molecular determinant for response to p53 reactivation therapy in conjunctival melanoma Oncogene 2021 Nov 17; PMID: 34785779